Oliver McCammon
Stock Analyst at LifeSci Capital
(4.88)
# 303
Out of 4,712 analysts
27
Total ratings
55.1%
Success rate
66.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oliver McCammon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLUE Monte Rosa Therapeutics | Reiterated: Buy | n/a | $14.15 | - | 16 | Sep 8, 2026 | |
| INBX Inhibrx Biosciences | Reiterated: Buy | $230 | $110.31 | +108.50% | 5 | Sep 8, 2026 | |
| CADL Candel Therapeutics | Reiterated: Buy | $16 | $11.55 | +38.53% | 6 | Aug 14, 2026 |
Monte Rosa Therapeutics
Sep 8, 2026
Reiterated: Buy
Price Target: n/a
Current: $14.15
Upside: -
Inhibrx Biosciences
Sep 8, 2026
Reiterated: Buy
Price Target: $230
Current: $110.31
Upside: +108.50%
Candel Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $16
Current: $11.55
Upside: +38.53%